Milnacipran-Associated Urinary Retention A Case Report

被引：5

作者：

Aggarwal, Ashish ^{[1
]}

Khandelwal, Ashish ^{[1
]}

Jiloha, Ram C. ^{[1
]}

机构：

[1] GB Pant Hosp, Dept Psychiat, New Delhi, India

来源：

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 2010年 / 30卷 / 05期

关键词：

TOLERABILITY; EFFICACY;

D O I：

10.1097/JCP.0b013e3181f05822

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：641 / 641

页数：1

共 4 条

[1] Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy [J].

Demyttenaere, K ;

Huygens, R ;

Van Buggenhout, R .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (06) :353-355

[2] Efficacy and tolerability of milnacipran: An overview [J].

Montgomery, SA ;

Prost, JF ;

Solles, A ;

Briley, M .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 :47-51

[3] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].

NARANJO, CA ;

BUSTO, U ;

SELLERS, EM ;

SANDOR, P ;

RUIZ, I ;

ROBERTS, EA ;

JANECEK, E ;

DOMECQ, C ;

GREENBLATT, DJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245

[4] SNRIs: The pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants [J].

Stahl, SM ;

Grady, MM ;

Moret, C ;

Briley, M .

CNS SPECTRUMS, 2005, 10 (09) :732-747

← 1 →